RxDoctor Payments Data

Yaseen Perbtani, DO

Internal Medicine · Gainesville, FLNPI 1851738892

Payments from drug & device makers

$46,543in general payments, 2019–2025

Across 103 payments — averaging $451.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$41K
  • Apollo Endosurgery US Inc$1K
  • Olympus America Inc.$1K
  • Medtronic$1K
  • Lumendi LLC$299
  • Conmed Corporation$238
  • plus $1K from 10 others

What the payments were for

  • Speaking & faculty fees$12,15526%
  • Grants$25,00054%
  • Travel & lodging$2,4185%
  • Food & beverage$6,96915%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific47$41,043
Apollo Endosurgery US Inc11$1,485
Olympus America Inc.14$1,237
Medtronic12$1,172
Lumendi LLC3$299
Conmed Corporation2$238
Endogastric Solutions, Inc4$220
Pentax Of America, Inc.1$162
Ambu Inc.1$141
AstraZeneca1$128
Novo Nordisk1$124
ERBE USA Inc1$100
AbbVie1$91
Olympus Latin America, Inc.1$61
Cook Medical LLC2$30
Pfizer1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,543 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$132,219
Medicare patients
523
Services billed
878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase19$31,532
LinzessLinaclotide24$16,949
Omeprazole167$2,277
Rabeprazole Sodium31$934
Dicyclomine Hcl19$853
Ondansetron OdtOndansetron17$499
Ondansetron Hcl22$434
Pantoprazole Sodium31$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$91$48,48143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →